http://app.newmediawire.com/news/5e3bf942d69a3a00049ada96/amarantus-announces-subsidiary-manf-therapeutics-enters-into-material-transfer-agreement-with-dyadic-international

New York, NY - ( NewMediaWire ) - February 06, 2020 - Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary therapeutics and diagnostics, as well as CBD Wellness through its subsidiaries, today announced that its wholly-owned subsidiary MANF Therapeutics has entered into a material transfer agreement (MTA) with Dyadic International, Inc. (Nasdaq:DYAI , or Dyadic) to transfer existing batches of mesencephalic astrocyte-derived neurotrophic factor (MANF) therapeutic protein previously manufactured by third parties in baculovirus and CHO to Dyadic to assist in the evaluation of the potential of Dyadic’s proprietary C1 biologics production platform to manufacture MANF for clinical and commercial use.  C1, based on the fungus Myceliophthora thermophila, is a microorganism which enables the development and large scale manufacture of low-cost biologics, and has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologics, including therapeutic proteins such as MANF.

Development rights to MANF were sublicensed from Amarantus to Emerald Organic Products, Inc. in December 2019. MANF has achieved pre-clinical proof of concept in retinitis pigmentosa (RP), retinal artery occlusion (RAO), glaucoma, age-related macular degeneration (AMD), Parkinson’s disease, diabetes, myocardial infarction, as well as several other endoplasmic reticulum stress-related disorders, and  has shown the potential to enhance immunological response in pre-clinical studies. Pre-clinical development of MANF is initially being focused on the treatment of orphan ophthalmological diseases and Parkinson’s. MANF has received orphan drug designation from the US FDA for the treatment of RP and RAO.